Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
Joint Authors
Busceti, Maria Teresa
Pelaia, Corrado
Calabrese, Cecilia
Garofalo, Eugenio
Vatrella, Alessandro
Pelaia, Girolamo
Terracciano, Rosa
Lombardo, N.
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-05-10
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Asthma is a very frequent chronic airway disease that includes many different clinical phenotypes and inflammatory patterns.
In particular, eosinophilic bronchial inflammation is often associated with allergic as well as nonallergic asthma.
The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2).
Hence, IL-5 and its receptor are suitable targets for selective biologic drugs which can play a key role in add-on treatment of severe eosinophilic asthma refractory to corticosteroids.
Within such a context, the anti-IL-5 monoclonal antibodies mepolizumab and reslizumab have been developed and approved for biological therapy of uncontrolled eosinophilic asthma.
In this regard, on the basis of several successful randomized controlled trials, the anti-IL-5 receptor benralizumab has also recently obtained the approval from US Food and Drug Administration (FDA).
American Psychological Association (APA)
Pelaia, Corrado& Calabrese, Cecilia& Vatrella, Alessandro& Busceti, Maria Teresa& Garofalo, Eugenio& Lombardo, N.…[et al.]. 2018. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
Modern Language Association (MLA)
Pelaia, Corrado…[et al.]. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
American Medical Association (AMA)
Pelaia, Corrado& Calabrese, Cecilia& Vatrella, Alessandro& Busceti, Maria Teresa& Garofalo, Eugenio& Lombardo, N.…[et al.]. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1126942
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1126942